JaLCDOI 10.18926/AMO/56254
FullText URL 72_5_535.pdf
Author Sato, Daisuke| Gohda, Tomohito| Kihara, Masao| Kanaguchi, Yasuhiko| Kobayashi, Takashi| Mano, Satoshi| Sasaki, Yu| Nohara, Nao| Murakoshi, Maki| Nakata, Junichiro| Suzuki, Hitoshi| Ueda, Seiji| Horikoshi, Satoshi| Suzuki, Yusuke|
Abstract Some patients with chronic kidney disease (CKD) receiving hemodialysis develop erythropoietin-resistant anemia, possibly due to zinc deficiency. The frequency of zinc deficiency in CKD (stages 1-5 and 5D) and CKD improvement via zinc supplementation are not completely verified. Here 500 CKD patients (Stage 1/2, n=100; Stage 3, n=100; Stage 4, n=100, Stage n=5, 100; Stage 5D, n=100) will be recruited to determine the frequency of serum zinc deficiency at each CKD stage. Patients with serum zinc concentrations <80 μg/dL will be treated with zinc acetate dihydrate (NobelzinR) to evaluate its effects on hypozincemia, taste disturbances, and anemia.
Keywords zinc acetate dihydrate anemia chronic kidney disease
Amo Type Clinical Study Protocol
Published Date 2018-10
Publication Title Acta Medica Okayama
Volume volume72
Issue issue5
Publisher Okayama University Medical School
Start Page 535
End Page 538
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30369613